BR9609335B1 - análogos de somatostatina, bem como composição farmacêutica compreendendo os mesmos. - Google Patents

análogos de somatostatina, bem como composição farmacêutica compreendendo os mesmos.

Info

Publication number: BR9609335B1
Authority: BR; Brazil
Prior art keywords: residue; ala; amino acid; well; pharmaceutical composition
Prior art date: 1995-06-29

Application number

BRPI9609335-8A

Other languages

English (en)

Other versions

BR9609335A (pt

BR9609335B8 (pt

Inventor

Rainer Albert

Wilfried Bauer

Christian Bruns

Nagarajan Chandramouli

Ian Lewis

Gisbert Weckbecker

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-29

Filing date

1996-06-28

Publication date

2009-08-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26307298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9609335(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-29 Priority claimed from GBGB9513224.7A external-priority patent/GB9513224D0/en

1996-01-10 Priority claimed from GBGB9600429.6A external-priority patent/GB9600429D0/en

1996-06-28 Application filed filed Critical

1999-05-25 Publication of BR9609335A publication Critical patent/BR9609335A/pt

2009-08-11 Publication of BR9609335B1 publication Critical patent/BR9609335B1/pt

2014-10-07 Publication of BR9609335B8 publication Critical patent/BR9609335B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C07K14/6555—Somatostatins at least 1 amino acid in D-form
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Immunology (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Rheumatology (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)

BRPI9609335-8B8A 1995-06-29 1996-06-28 Análogos de somatostatina, bem como composição farmacêutica compreendendo os mesmos. BR9609335B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9513224.7A GB9513224D0 (en)	1995-06-29	1995-06-29	Organic compounds
GBGB9600429.6A GB9600429D0 (en)	1996-01-10	1996-01-10	Organic compounds
PCT/EP1996/002840 WO1997001579A2 (en)	1995-06-29	1996-06-28	Somatostatin peptides

Publications (3)

Publication Number	Publication Date
BR9609335A BR9609335A (pt)	1999-05-25
BR9609335B1 true BR9609335B1 (pt)	2009-08-11
BR9609335B8 BR9609335B8 (pt)	2014-10-07

Family

ID=26307298

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI9609335-8B8A BR9609335B8 (pt)	1995-06-29	1996-06-28	Análogos de somatostatina, bem como composição farmacêutica compreendendo os mesmos.

Country Status (24)

Country	Link
US (1)	US6225284B1 (pt)
EP (1)	EP0835263B9 (pt)
JP (2)	JP3445796B2 (pt)
KR (1)	KR100454664B1 (pt)
CN (1)	CN1156492C (pt)
AT (1)	ATE210152T1 (pt)
AU (1)	AU714447B2 (pt)
BR (1)	BR9609335B8 (pt)
CA (1)	CA2222524C (pt)
CZ (1)	CZ297381B6 (pt)
DE (1)	DE69617687T2 (pt)
DK (1)	DK0835263T3 (pt)
ES (1)	ES2169251T3 (pt)
HU (1)	HU228984B1 (pt)
IL (1)	IL122243A (pt)
MY (1)	MY147327A (pt)
NO (1)	NO317867B1 (pt)
NZ (1)	NZ313147A (pt)
PL (1)	PL184947B1 (pt)
PT (1)	PT835263E (pt)
SK (1)	SK284087B6 (pt)
TR (1)	TR199701718T1 (pt)
TW (1)	TW491854B (pt)
WO (1)	WO1997001579A2 (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7238340B1 (en) *	1991-11-27	2007-07-03	Cis Bio International	Monoamine, diamide, thiol-containing metal chelating agents
JPH10251296A (ja) *	1997-03-06	1998-09-22	American Cyanamid Co	ソマトスタチン拮抗薬として有用なペプチド
US6004928A (en) *	1997-05-13	1999-12-21	Biomeasure, Incorporated	Method of treating hyperlipidemia
ATE245998T1 (de)	1997-05-13	2003-08-15	Sod Conseils Rech Applic	Somatostatin agoniste zur reduzierung von körpergewicht
WO1998051330A1 (en)	1997-05-13	1998-11-19	Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.)	Method and compositions for treating hyperlipidemia and other conditions
US5968903A (en) *	1998-05-07	1999-10-19	Biomeasure, Incorporated	Inhibition of H. pylori proliferation
SE9802080D0 (sv) *	1998-06-11	1998-06-11	Hellstroem	Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
US6608027B1 (en)	1999-04-06	2003-08-19	Boehringer Ingelheim (Canada) Ltd	Macrocyclic peptides active against the hepatitis C virus
US6358491B1 (en)	1999-08-27	2002-03-19	Berlex Laboratories, Inc.	Somatostatin analogs
JP2003514867A (ja) *	1999-11-29	2003-04-22	スミスクライン・ビーチャム・コーポレイション	ウロテンシン−ｉｉ環状類似物
GB0018891D0 (en) *	2000-08-01	2000-09-20	Novartis Ag	Organic compounds
US7122172B1 (en)	2000-03-08	2006-10-17	Gerhart Graupner	Methods and compositions for targeted drug delivery
US7906103B2 (en) *	2000-03-08	2011-03-15	Gerhard Graupner	Methods and compositions for targeted drug delivery
CA2449634C (en)	2001-06-08	2011-08-02	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R	Somatostatin-dopamine chimeric analogs
US7189856B2 (en) *	2001-12-28	2007-03-13	Gideon Shapiro	Non-peptide somatostatin receptor ligands
US20050260259A1 (en) *	2004-04-23	2005-11-24	Bolotin Elijah M	Compositions for treatment with glucagon-like peptide, and methods of making and using the same
JP2005524657A (ja) *	2002-02-27	2005-08-18	ファーメイン，エルティーディー．	治療剤及び他の物質を送達するための組成物、及び、前記組成物を作製し使用する方法
US7635463B2 (en) *	2002-02-27	2009-12-22	Pharmain Corporation	Compositions for delivery of therapeutics and other materials
US7122622B2 (en)	2002-04-16	2006-10-17	Biosynthema Inc.	Peptide compounds having improved binding affinity to somatostatin receptors
EP1358890A1 (en)	2002-05-03	2003-11-05	BioSynthema, Inc	Benzothienyl analogue of somatostatine, selective for certain somatostatin receptors
MY140680A (en) *	2002-05-20	2010-01-15	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
DE60324552D1 (en)	2002-05-20	2008-12-18	Bristol Myers Squibb Co	Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
AU2003299519A1 (en) *	2002-05-20	2004-05-04	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
DE60334205D1 (en)	2002-05-20	2010-10-28	Bristol Myers Squibb Co	Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
MXPA05005469A (es) *	2002-11-25	2005-09-08	Attenuon Llc	Peptidos que inhibien angiogenesis, migracion celular, invasion celular y proliferacion celular, composiciones y usos de los mismos.
BRPI0317176B1 (pt) *	2002-12-12	2018-03-13	Novartis Ag	Processo para a síntese de peptídeos contendo uma subestrutura de 4-hidróxi-prolina
GB0229020D0 (en) *	2002-12-12	2003-01-15	Novartis Ag	Organic compounds
GB0300095D0 (en) *	2003-01-03	2003-02-05	Novartis Ag	Organic compounds
WO2004093807A2 (en)	2003-04-22	2004-11-04	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Somatostatin vectors
PE20050285A1 (es)	2003-06-24	2005-06-09	Novartis Ag	Composicion farmaceutica que comprende analogos ciclicos de somatostatina
ES2361997T3 (es)	2003-09-22	2011-06-27	Boehringer Ingelheim International Gmbh	Péptidos macrocíclicos activos contra el virus de la hepatitis c.
EP1522311A1 (fr) *	2003-10-10	2005-04-13	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
US7132504B2 (en)	2003-11-12	2006-11-07	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
GB0326602D0 (en) *	2003-11-14	2003-12-17	Novartis Ag	Organic compounds
MY158342A (en)	2003-11-14	2016-09-30	Novartis Ag	Pharmaceutical composition
US7135462B2 (en)	2003-11-20	2006-11-14	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7309708B2 (en)	2003-11-20	2007-12-18	Birstol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2005070955A1 (en)	2004-01-21	2005-08-04	Boehringer Ingelheim International Gmbh	Macrocyclic peptides active against the hepatitis c virus
GB0428151D0 (en)	2004-12-22	2005-01-26	Novartis Ag	Organic compounds
EP1717247A1 (en) *	2005-04-28	2006-11-02	Schering AG	Cyclic peptides binding to the somatostatin receptor
WO2006114324A1 (en) *	2005-04-28	2006-11-02	Schering Ag	Compounds comprising cyclized somatostatin receptor binding peptides
EP1941902A1 (en) *	2007-01-02	2008-07-09	Novartis AG	Use of Somatostatin analogs in cluster headache
MX2009013830A (es) *	2007-06-29	2010-03-01	Gilead Sciences Inc	Compuestos antivirales.
KR101596524B1 (ko)	2007-06-29	2016-02-22	길리애드 사이언시즈, 인코포레이티드	항바이러스 화합물
CA2705977C (en)	2007-11-28	2016-06-14	Novartis Ag	Use of somatostatin analogs in meningioma
EP2067786A1 (en)	2007-12-07	2009-06-10	ITALFARMACO S.p.A.	Novel non selective analogs of somatostatin
SI2225271T1 (sl) *	2007-12-03	2013-10-30	Italfarmaco S.P.A.	Novi selektivni analogi somatostatina
CN102083451A (zh)	2008-06-12	2011-06-01	赛恩泰新公司	癌症的抑制
CA2727082C (en)	2008-06-12	2019-02-26	Syntaxin Limited	Fusion proteins for use in suppression of acromegaly
WO2010003939A1 (en) *	2008-07-08	2010-01-14	Novartis Ag	Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia
EP2172189A1 (en)	2008-10-01	2010-04-07	Novartis AG	Pharmaceutical Compositions
EP2213307A1 (en)	2009-02-03	2010-08-04	Novartis AG	Injectable depot formulations
EP2168983A1 (fr)	2008-09-30	2010-03-31	Ipsen Pharma	Nouveaux composés octapeptidiques et leur utilisation thérapeutique
GB0820970D0 (en)	2008-11-17	2008-12-24	Syntaxin Ltd	Suppression of cancer
WO2010080389A1 (en) *	2008-12-19	2010-07-15	Gilead Sciences, Inc.	Hcv ns3 protease inhibitors
EP2380596A1 (en) *	2010-04-20	2011-10-26	Technische Universität München	Cyclopentapeptide derivatives and uses thereof
US20210317161A1 (en)	2014-12-19	2021-10-14	Auro Peptides Ltd	A process for the preparation of pasireotide
CN106432429A (zh) *	2016-10-24	2017-02-22	合肥国肽生物科技有限公司	一种帕西瑞肽的合成方法
SI3568205T1 (sl)	2017-01-12	2023-12-29	Radiomedix Inc.	Zdravljenje rakastih celic, ki prekomerno izražajo receptorje za somatostatin, z uporabo derivatov okreotida, kelatiranih v radioizotope
TW202517303A (zh)	2018-07-25	2025-05-01	法商高級催化劑應用品有限公司	穩定的、濃縮的放射性核種錯合物溶液
US10596276B2 (en)	2018-07-25	2020-03-24	Advanced Accelerator Applications (Italy) S.R.L.	Stable, concentrated radionuclide complex solutions
US10596278B2 (en)	2018-07-25	2020-03-24	Advanced Accelerator Applications (Italy) S.R.L.	Stable, concentrated radionuclide complex solutions
CN119708199A (zh) *	2023-09-27	2025-03-28	钱杭江医药科技(嘉兴)有限公司	生长抑素肽类类似物、螯合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3863008A (en) *	1973-06-11	1975-01-28	American Home Prod	Somatostatin as stimulant of luteinizing hormone secretion
NZ195303A (en) *	1979-10-31	1984-10-19	Merck & Co Inc	Cyclic hexapeptide somatostatin analogues,and pharmaceutical compositions
US4292972A (en) *	1980-07-09	1981-10-06	E. R. Squibb & Sons, Inc.	Lyophilized hydrocolloio foam
US4505897A (en) *	1983-04-18	1985-03-19	The Administrators Of The Tulane Educational Fund	Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith
US4612366A (en)	1985-06-17	1986-09-16	Merck & Co., Inc.	Cyclic hexapeptide somatostatin analogs
CA2012115C (en)	1989-03-15	2001-07-03	Biomeasure, Inc.	Iodinated somatostatins
WO1990012811A1 (en)	1989-04-26	1990-11-01	The Administrators Of The Tulane Educational Fund	Linear somatostatin analogs
US5716596A (en) *	1992-06-23	1998-02-10	Diatide, Inc.	Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
SG48977A1 (en)	1993-06-23	1998-05-18	Diatide Inc	Radiolabeled peptides

1996
- 1996-06-27 MY MYPI96002639A patent/MY147327A/en unknown
- 1996-06-28 AU AU65150/96A patent/AU714447B2/en not_active Expired
- 1996-06-28 US US08/981,426 patent/US6225284B1/en not_active Expired - Lifetime
- 1996-06-28 TR TR97/01718T patent/TR199701718T1/xx unknown
- 1996-06-28 SK SK1770-97A patent/SK284087B6/sk not_active IP Right Cessation
- 1996-06-28 AT AT96924811T patent/ATE210152T1/de active
- 1996-06-28 DE DE69617687T patent/DE69617687T2/de not_active Expired - Lifetime
- 1996-06-28 HU HU9901455A patent/HU228984B1/hu unknown
- 1996-06-28 IL IL12224396A patent/IL122243A/xx not_active IP Right Cessation
- 1996-06-28 BR BRPI9609335-8B8A patent/BR9609335B8/pt not_active IP Right Cessation
- 1996-06-28 JP JP53683496A patent/JP3445796B2/ja not_active Expired - Lifetime
- 1996-06-28 CZ CZ0419697A patent/CZ297381B6/cs not_active IP Right Cessation
- 1996-06-28 PT PT96924811T patent/PT835263E/pt unknown
- 1996-06-28 CA CA2222524A patent/CA2222524C/en not_active Expired - Lifetime
- 1996-06-28 WO PCT/EP1996/002840 patent/WO1997001579A2/en not_active Ceased
- 1996-06-28 CN CNB961951206A patent/CN1156492C/zh not_active Expired - Lifetime
- 1996-06-28 EP EP96924811A patent/EP0835263B9/en not_active Expired - Lifetime
- 1996-06-28 ES ES96924811T patent/ES2169251T3/es not_active Expired - Lifetime
- 1996-06-28 NZ NZ313147A patent/NZ313147A/xx not_active IP Right Cessation
- 1996-06-28 KR KR1019970709796A patent/KR100454664B1/ko not_active Expired - Lifetime
- 1996-06-28 PL PL96323943A patent/PL184947B1/pl unknown
- 1996-06-28 DK DK96924811T patent/DK0835263T3/da active
- 1996-08-06 TW TW085109489A patent/TW491854B/zh not_active IP Right Cessation
1997
- 1997-12-23 NO NO19976064A patent/NO317867B1/no not_active IP Right Cessation
2002
- 2002-07-17 JP JP2002208012A patent/JP2003104998A/ja active Pending

Also Published As

Publication number	Publication date
EP0835263A2 (en)	1998-04-15
DE69617687T2 (de)	2002-08-22
CZ419697A3 (cs)	1998-05-13
WO1997001579A3 (en)	1997-02-27
HUP9901455A3 (en)	2000-11-28
CN1156492C (zh)	2004-07-07
IL122243A0 (en)	1998-04-05
JP2003104998A (ja)	2003-04-09
US6225284B1 (en)	2001-05-01
KR100454664B1 (ko)	2005-09-12
DE69617687D1 (de)	2002-01-17
JP3445796B2 (ja)	2003-09-08
PT835263E (pt)	2002-04-29
SK177097A3 (en)	1998-08-05
PL184947B1 (pl)	2003-01-31
NO976064L (no)	1998-02-16
CZ297381B6 (cs)	2006-11-15
EP0835263B1 (en)	2001-12-05
MY147327A (en)	2012-11-30
HU228984B1 (en)	2013-07-29
BR9609335A (pt)	1999-05-25
AU6515096A (en)	1997-01-30
SK284087B6 (sk)	2004-09-08
AU714447B2 (en)	2000-01-06
KR19990028480A (ko)	1999-04-15
ATE210152T1 (de)	2001-12-15
CA2222524A1 (en)	1997-01-16
TR199701718T1 (xx)	1998-05-21
CN1189166A (zh)	1998-07-29
NO976064D0 (no)	1997-12-23
NO317867B1 (no)	2004-12-27
HUP9901455A2 (hu)	1999-09-28
WO1997001579A2 (en)	1997-01-16
JPH11506108A (ja)	1999-06-02
PL323943A1 (en)	1998-04-27
CA2222524C (en)	2010-01-26
TW491854B (en)	2002-06-21
NZ313147A (en)	1999-11-29
IL122243A (en)	2005-09-25
EP0835263B9 (en)	2002-07-24
DK0835263T3 (da)	2002-04-02
ES2169251T3 (es)	2002-07-01
BR9609335B8 (pt)	2014-10-07

Publication	Publication Date	Title
BR9609335B1 (pt)	2009-08-11	análogos de somatostatina, bem como composição farmacêutica compreendendo os mesmos.
ES2063350T3 (es)	1995-01-01	Nuevas proteinas con efecto inhibidor del tnf y su produccion.
ATE245659T1 (de)	2003-08-15	Insulinabkömmlinge
KR870002163A (ko)	1987-03-30	펩티드의 제조방법
ATE168719T1 (de)	1998-08-15	Osteogene peptide
MX9709962A (es)	1998-03-31	Peptidos de somatostatina.
DK0479912T3 (da)	1994-10-10	Fremgangsmåde til hæmning af N-endereglens forløb i levende celler
KR840007569A (ko)	1984-12-08	Grf 유사체 펩티드의 제법
DE3780000D1 (de)	1992-07-30	Peptidverbindungen.
ATE146188T1 (de)	1996-12-15	Substituierungsanaloge von magaininpeptiden
KR870000356A (ko)	1987-02-18	메티오닐 단백질로부터 n-말단 메티오닌을 제거하는 방법
Suzuki et al.	1990	Primary structure of a constituent polypeptide chain (AIII) of the giant haemoglobin from the deep-sea tube worm Lamellibrachia. A possible H2S-binding site
Wakabayashi et al.	1980	Amino Acid Sequences of Two Ferredoxins from Phytolacca esculenta Gene Duplication and Speciation
KR890701628A (ko)	1989-12-21	단백질(성) 감미제의 제조
KNORR et al.	1983	[B17-D-Leucine] Insulin and [B17-Norleucine] Insulin: synthesis and biological properties
WO2003044159A9 (en)	2013-10-31	Zinc finger proteins, polynucleotides encoding same and antibodies thereto
SE8700761L (sv)	1988-06-23	Tillempningar av en polypeptid

Legal Events

Date	Code	Title	Description
2004-09-14	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2007-08-21	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2009-03-31	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2009-09-22	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/09/2009, OBSERVADAS AS CONDICOES LEGAIS.
2013-10-08	B22O	Other matters related to patents and certificates of addition of invention: legal action concerning patent	Free format text: INPI-52400.062008/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132270-62.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU:NIPPON KAYAKU KABUSHIKI KAISHA, NOVARTIS AG, NOVARTIS SA, NOVARTISINS, NOVARTIS CONSUMER HEALTH S.A.
2014-09-30	B19A	Notification of judicial decision: notification of judicial decision	Free format text: INPI-52400.104054/2014 SECAO JUDICIARIA DO RIO DE JANEIRO 13A VARA FEDERAL PROCESSO NO 2014.51.01.001852-6 AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL INPI REU: NOVARTIS AG E OUTROS DECISAO: ANTECIPO OS EFEITOS DA TUTELA, A FIM DE DETERMINAR A IMEDIATA READEQUACAO DO PRAZO DE VIGENCIA DA PATENTE PI9609335-8 PARA VINTE ANOS CONTADOS A PARTIR DO RESPECTIVO DEPOSITO, NOS TERMOS DO PARAGRAFO UNICO DO ART. 229 C/C O CAPUT DO ART. 40 DA LPI, CONFORME TABELA A SEGUIR: NOME DO TITULAR: NOVARTIS AG -PATENTE: PI9609335-8-PRAZO DE VIGENCIA:28/06/2016
2014-10-07	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: REFERENTE A RPI 2020 DE 22/09/2009, POR DETERMINACAO DA 13A VARA FEDERAL DO RIO DE JANEIRO, QUANTOAO PRAZO DE VALIDADE.
2016-02-16	B19A	Notification of judicial decision: notification of judicial decision	Free format text: INPI-52400.104054/2014 - SECAO JUDICIARIA DO RIO DE JANEIRO 13A VARA FEDERAL PROCESSO NO0001852-02.2014.4.02.5101 AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL INPI F REU: NOVARTIS AG E OUTROS DECISAO: DETERMINAR EM DEFINITIVO ADEQUACAO DO PRAZO DE VIGENCIA DA PATENTE PI9609335-8 PARA VINTE ANOS CONTADOS A PARTIR DO RESPECTIVO DEPOSITO, CONFORME TABELA ABAIXO: TITULAR: NOVARTIS AG PI9609335-8 PRAZO DE VIGENCIA: 28/06/2016
2016-07-05	B21A	Patent or certificate of addition expired [chapter 21.1 patent gazette]	Free format text: PATENTE EXTINTA EM 28/06/2016